Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder.
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2014
At a glance
- Drugs LUAA 39959 (Primary) ; Quetiapine
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Sponsors Lundbeck A/S
- 16 Sep 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 05 Jun 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 19 Dec 2008 Status changed from not yet recruiting to recruiting.